Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies - Episode 6

Pirtobrutinib in the Management of R/R CLL: Updates from the BRUIN Trial

,

Panelists discuss how the non-covalent BTK inhibitor pirtobrutinib has shown promising results in the BRUIN clinical trials for both BTK inhibitor-naive and previously treated chronic lymphocytic leukemia patients, reviewing key efficacy and safety data presented at recent hematology conferences.

Video content above is prompted by the following: